P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

BACKGROUND: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be associated with the O(6)-methylguanine DNA methyltransferase (MGMT) promoter methyl...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Seystahl, K, Hentschel, B, Loew, S, Gramatzki, D, Felsberg, J, Herrlinger, U, Westphal, M, Schackert, G, Thon, N, Schlegel, U, Tatagiba, M, Pietsch, T, Reifenberger, G, Löffler, M, Wick, W, Weller, M
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Poster Presentations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.343
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料